Immutep Ltd has released a press release.
Appendix 4E & 2025 Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
- FDA feedback received for head & neck cancer in CPS below 1
- Immutep Quarterly Activities Report Q4 FY25
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
- Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Later from Immutep
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
- New investigator-initiated Phase II trial for Efti
- Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
- TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
- Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep